Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Date:7/30/2009

---- ---- ---- ---- Operating expenses Research and development $4,648 $5,501 $11,524 $11,510 General and administrative 2,532 1,975 4,587 4,020 ----- ----- ----- ----- Total operating expenses(1) 7,180 7,476 16,111 15,530 Interest income and other, net 210 384 381 995 Gain from valuation of common stock warrant liability 440 - 440 - --- --- --- --- Total other income, net 650 384 821 995 Net loss(1) $(6,530) $(7,092) $(15,290) $(14,535) ======= ======= ======== ======== Net loss per share, basic and diluted(1) $(0.21) $(0.25) $(0.51) $(0.51) ====== ====== ====== ====== Shares used in calculating net loss per share, basic and diluted 31,493 28,731 30,173 28,714 ====== ====== ====== ====== (1) Includes non-cash operating expenses of $1,062 and $668 determined in accordance with Statement of Financial Accounts Standards No. 123(R), "Share-Based Payment" (SFAS No. 123(R)) or approximately $0.03 and $0.02 effect on basic and diluted net loss per common share for the three months ended June 30, 2009 and 2008, respectively. Research and development expense and general and administrative expense includes $616 and $446, respectively, of non-cash operating expenses determined in accordance with SFAS No. 123(R) for the three months ended June 30, 2009. Includes non-cash operating expenses of $1,746 and $1,329 determined in
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
2. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
3. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
5. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
6. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
7. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
8. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
9. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
10. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
11. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce ... V19 with PVM technology , is now available. ... measurement tool continuously captures high-resolution images under a ... automatically prepares a report pairing the most relevant ... changes. This compelling blend of high resolution images ...
(Date:12/15/2014)... , Dec. 15, 2014  GlassesOff Inc. (OTCBB: GLSO) ... as an independent director of the Company,s Board ... AeroScout and served as its CEO until its acquisition ... a $240 million transaction. Recognized as the inventor of ... leadership, AeroScout provided Wi-Fi -based RFID solutions focused on ...
(Date:12/13/2014)... December 13, 2014 CanDiag, Inc., a ... company has changed its name to OncoTab, Inc. ... of where we are today,” said CEO and Chief ... platform’s applications beyond breast cancer diagnostics to include imaging ... of that evolution.” , Founded in 2011 by Dr. ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2
... , , , ... Transcriptor Reverse Transcriptase in,the Eberwine Target Preparation Workflow , ... , , Reproducibility and sensitivity are key parameters ... microarray,platforms has shifted the focus to target preparation as a,critical step in microarray ...
... , , ... , , Over the past decade, many organisms ... of gene sequences are now ready,for functional analysis. Knowledge of tissues and cells,that ... , , , , ...
... , , ... Roche Applied Science now offers new larger pack sizes,of PCR-Grade Nucleotides. These larger pack ... , , , Single dNTPs , ... , Single dNTPs are now available in 500-mol pack sizes.,The Deoxynucleoside ...
Cached Biology Technology:Increased Sensitivity in Microarray Analysis 2Increased Sensitivity in Microarray Analysis 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 2The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 4The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 5The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 6PCR-Grade Nucleotides,Larger Pack Sizes Now Available 2
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... off on a sun-powered adventure this autumn when the Durham ... Challenge. Using nothing but solar power, the DUSC team ... of Australia to Adelaide in the south. The Durham ... in mid-August after taking part in endurance testing in the ...
... Milan, Italy, August 11, 2011 Memory is not a ... on different areas of the brain. Episodic memory, the ability ... is known to be vulnerable to brain damage involving the ... hippocampus occurs very early in life? In a case study ...
... Loligo bleekeri ) employ different reproductive strategies depending on their ... BMC Evolutionary Biology shows that the divergent mating ... different sperm sizes. Large male squid compete for females ... female has chosen her partner they mate in an above ...
Cached Biology News:Durham University solar car takes on World Solar Challenge 2When you can recite a poem but not remember who asked you to learn it a few days earlier 2
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: